Research Topic

Integrin αvβ3, Nonpeptide Hormones, and Cancer

About this Research Topic

Integrin αvβ3 is one of a family of structural heterodimeric proteins of the plasma membrane that interact with extracellular matrix proteins and are generously expressed by cancer cells and dividing endothelial cells. It is now known that receptor sites for nonpeptide hormones, such as thyroid hormone and steroids, exist on αvβ3 and nongenomically mediate actions of these hormones on cancer cell proliferation and on angiogenesis. These receptor sites share no structural homologies with nuclear receptors for nonpeptide hormones that mediate genomic actions. However, the αvβ3 receptors may modulate expression of specific genes relevant to cancer cell survival and may control from the cell surface the activating phosphorylation of nuclear hormone receptors.

For this issue of the journal, we will invite papers dealing with cancer- and angiogenesis-relevant actions at αvβ3 of thyroid hormone, thyroid hormone analogues and sex steroids, including a stilbenoid (resveratrol). Papers will also describe use of hormone receptor sites on αvβ3 to image cancers and describe chemically modified hormones with payload capabilities which target hormone receptor sites on αvβ3 for delivery of anticancer drugs.


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Integrin αvβ3 is one of a family of structural heterodimeric proteins of the plasma membrane that interact with extracellular matrix proteins and are generously expressed by cancer cells and dividing endothelial cells. It is now known that receptor sites for nonpeptide hormones, such as thyroid hormone and steroids, exist on αvβ3 and nongenomically mediate actions of these hormones on cancer cell proliferation and on angiogenesis. These receptor sites share no structural homologies with nuclear receptors for nonpeptide hormones that mediate genomic actions. However, the αvβ3 receptors may modulate expression of specific genes relevant to cancer cell survival and may control from the cell surface the activating phosphorylation of nuclear hormone receptors.

For this issue of the journal, we will invite papers dealing with cancer- and angiogenesis-relevant actions at αvβ3 of thyroid hormone, thyroid hormone analogues and sex steroids, including a stilbenoid (resveratrol). Papers will also describe use of hormone receptor sites on αvβ3 to image cancers and describe chemically modified hormones with payload capabilities which target hormone receptor sites on αvβ3 for delivery of anticancer drugs.


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

30 March 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

30 March 2018 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Comments

Loading..

Add a comment

Add comment
Back to top